Prolonged delivery of peptides

Details Prolonged delivery of peptides Prolonged delivery of peptides

1995-06-07

2001-09-04

Huff, Sheela (Department: 1642)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S324000

Reexamination Certificate

active

06284727

ABSTRACT:

BACKGROUND OF THE INVENTION
The present invention relates to compositions and methods for the treatment of Diabetes Mellitus. More specifically, the present invention relates to compositions to prolong the administration of glucagon-like peptide 1 (GLP-1), and derivatives thereof. These compositions are useful in treatment of Non-Insulin Dependent Diabetes Mellitus (NIDDM).
The amino acid sequence of GLP-1 is known as:
His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly (SEQUENCE ID NO: 1)
GLP-1 is disclosed by Lopez, L. C., et al., P.N.A.S., USA 80: 5485-5489 (1983); Bell, G. I., et al., Nature 302: 716-718 (1983); Heinrich, G. et al., Endocrinol. 115: 2176-2181 (1984) and Ghiglione, M., et al., Diabetologia 27: 599-600 (1984).
During processing in the pancreas and intestine, GLP-1 is converted to a 31 amino acid peptide having amino acids 7-37 of GLP-1, hereinafter this peptide is referred to as GLP-1 (7-37).
This peptide has been shown to have insulinotropic activity, that is, it is able to stimulate, or cause to be stimulated, the synthesis or expression of the hormone insulin. Because of this insulinotropic activity, GLP-1 (7-37) is alternatively referred to as insulinotropin.
GLP-1 (7-37) has the following amino acid sequence:
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly (SEQUENCE ID NO: 2).
GLP-1 (7-37), certain derivatives thereof and the use thereof to treat Diabetes mellitus in a mammal are disclosed in U.S. Pat. Nos. 5,118,666 ('666 patent) and 5,120,712 ('712 patent), the disclosures of these patents being incorporated herein by reference. The derivatives of GLP-1 (7-37) disclosed in the '666 and '712 patents include polypeptides which contain or lack one of more amino acids that may not be present in the naturally occurring sequence. Further derivatives of GLP-1 (7-37) disclosed in the '666 and '712 patents include certain C-terminal salts, esters and amides where the salts and esters are defined as OM where M is a pharmaceutically acceptable cation or a lower (C
1
-C
6
) branched or unbranched alkyl group and the amides are defined as —NR
2
R
3
where R
2
and R
3
are the same or different and are selected from the group consisting of hydrogen and a lower (C
1
-C
6
) branched or unbranched alkyl group.
Certain other polypeptides, alternatively referred to as truncated GLP-1 or truncated insulinotropin, having insulinotropic activity and the derivatives thereof are disclosed in PCT/US 89/01121 (WO 90/11296). Those polypeptides, referred to therein as GLP-1 (7-36), GLP-1 (7-35) and GLP-1 (7-34) have the following amino acid sequences, respectively.
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg (SEQUENCE ID NO: 3);
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly (SEQUENCE ID NO: 4); and
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys (SEQUENCE ID NO: 5);
Derivatives of the polypeptides disclosed in PCT/US89/01121 include polypeptides having inconsequential amino acid substitutions, or additional amino acids to enhance coupling to carrier protein or to enhance the insulinotropic effect thereof. Further derivatives of insulinotropin disclosed in PCT/US89/01121 include certain C-terminal salts, esters and amides where the salts and esters are defined as OM where M is a pharmaceutically acceptable cation or a lower branched or unbranched alkyl group and the amides are defined as —NR
2
R
3
where R
2
and R
3
are the same or different and are selected from the group consisting of hydrogen and a lower branched or unbranched alkyl group.


REFERENCES:
patent: 4654324 (1987-03-01), Chance et al.
patent: 4857505 (1989-08-01), Ardent
patent: 4985404 (1991-01-01), Mitchell
patent: 5118666 (1992-06-01), Habener
patent: 5120712 (1992-06-01), Habener
patent: 5175145 (1992-12-01), Cooper
patent: 5424286 (1995-06-01), Eng
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5574008 (1996-11-01), Johnson et al.
patent: 5614492 (1997-03-01), Habener
patent: 5631224 (1997-05-01), Efendic
patent: 19530865 A1 (1997-02-01), None
patent: 0 177 478 (1986-04-01), None
patent: 0 343 696 A2 (1989-11-01), None
patent: 0 442 671 A2 (1991-08-01), None
patent: 0 473 268 A3 (1992-03-01), None
patent: 0 526 862 A1 (1993-02-01), None
patent: 0 619 322 A2 (1994-10-01), None
patent: 0 658 568 A1 (1995-06-01), None
patent: 0 733 644 A1 (1996-09-01), None
patent: 2 732 894 (1996-10-01), None
patent: 06941 (1987-11-01), None
patent: WO 88/07366 (1988-10-01), None
patent: WO 90/02835 (1990-03-01), None
patent: 11296 (1990-10-01), None
patent: 11457 (1991-08-01), None
patent: WO 93/18786 (1993-09-01), None
patent: WO 93/19175 (1993-09-01), None
patent: WO 93/18785 (1993-09-01), None
patent: WO 93/25579 (1993-12-01), None
patent: WO 95/07098 (1995-03-01), None
patent: WO 95/05848 (1995-03-01), None
patent: WO 95/17510 (1995-06-01), None
patent: WO 95/31214 (1995-11-01), None
patent: WO 96/20005 (1996-04-01), None
Kreymann et al, Laneef Dec. 5, 1987 p. 1300.*
Conn's Current Therapy p. 483. (1989).*
Remington's Pharmaceutical Sciences, 16th ed. p. 1555, 1467, 1453, 1451, 1450, 1448, CH 91, 1980.*
Cross et al., “Subcutaneous Absorption Kinetics And Local Tissue Distribution Of Interferon And Other Solutes,” J. Pharm. Pharmacol., 1993, 45, pp. 606-609.
Hirano et al., “Studies on the Absorption of Practically Water-Insolable Drugs Following Injection VIII: Comparison of the Subcutaneous Absorption Rates From Aqueous Suspensions in the Mouse, Rat and Rabbit,” J. Pharm. Sci., 1993, 72(6), pp. 608-612.
Nara et al., “A New Method for Assessment of Drug Absorption From Muscle: Application of a Local Perfusion System,” J. Pharm. Pharmacol, 1991, 43, pp. 272-274.
Dickert et al., “Absorption of NPH-Insulin from Subcutaneous Tissue: A Methodological Study in Pigs,” ACTA Pharmacol et Toxicol, 1982, 51, pp. 30-37.
Supersaxo et al., “Effects of Molecular Weight on the Lymphatic Absorption of Water-Soluble Compounds Following Subcutanous Administration,” Pharmaceutical Research, 1990, 7(2), pp. 167-169.
Mosjov, “Structural Requirements for Biological Activity of Glucagon-Like Peptide-1, ” Int. J. Peptide Protein Res., 1992, 40, pp. 333-343.
Suzuki et al., “Comparison of the Effects of Various C-Terminal and N-Terminal Fragment Peptide of Glucogen-Like Peptide-1 or Insulin and Glucagon Release from the Isolated Perfused Rat Pancreas,” Endocrinology, 1989, 125(6), pp. 3109-3113.
Krówczyński, Leszek, “Technologia postaci leków (Technology of the drug forms)”, Państwowy Zaklad Wydawnictw Lekarskich Warszawa, 1969, pp. 220, 463-464, 490, 502.
Gennaro, Alfonso R., Chapter 23 in Remington's Pharmaceutical Sciences, 16th edition, A. Osol Editor, Mack Publishing Company, Easton, PA, 1980, pp. 343-363.
Gill, I. J. et al., “Cyclodextrins as protection agents against enhancer damage in nasal delivery systems II. Effect on in vivo absorption of insulin and histopathology of nasal membrane,”European Journal of Pharmaceutical Sciences1:237-248, Jun. 1994.
Hendrick, G.K. et al., “Glucagon-like Peptide-I-(7-37) Suppresses Hyperglycemia in Rats,”Metabolism42(1):1-6, Jan. 1993.
Holst, J.J. et al., “Truncated glucago-like peptide I, an insulin-releasing hormone for the distal gut,”FEBS Letters211(2):169-174, Jan. 1987.
Remington'Pharmaceutical Sciences, 16th ed. pp. 1555, 1467, 1453, 1451, 1450, 1448, Ch. 91, 1980.*
Cross et al., “Subcutaneous Absorption Kinetics and Local Tissue Distribution of Interferon and other Soluter,” J. Pharm. Pharmacol., 1993, 45, pp. 606-609;.
Hirano et al., “Studies on the Absorption of Practically Water-Insoluble Drugs following Injection VIII: Comparison of the Subcutaneous Absorption Rates from Aqueous Suspensions in the Mouse, Rat, and Rabbit,” J. Pharm. Sci., 1993, 72(6),

Affiliated with

Also associated with

Rating

Prolonged delivery of peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prolonged delivery of peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prolonged delivery of peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2454346